Literature DB >> 10205772

Estimating potency for the Emax-model without attaining maximal effects.

R C Schoemaker1, J M van Gerven, A F Cohen.   

Abstract

The most widely applied model relating drug concentrations to effects is the Emax model. In practice, concentration-effect relationships often deviate from a simple linear relationship but without reaching a clear maximum because a further increase in concentration might be associated with unacceptable or distorting side effects. The parameters for the Emax model can only be estimated with reasonable precision if the curve shows sign of reaching a maximum, otherwise both EC50 and Emax estimates may be extremely imprecise. This paper provides a solution by introducing a new parameter (S0) equal to Emax/EC50 that can be used to characterize potency adequately even if there are no signs of a clear maximum. Simulations are presented to investigate the nature of the new parameter and published examples are used as illustration.

Mesh:

Substances:

Year:  1998        PMID: 10205772     DOI: 10.1023/a:1023277201179

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  10 in total

1.  Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual volunteers.

Authors:  A L van Steveninck; S Verver; H C Schoemaker; M S Pieters; R Kroon; D D Breimer; A F Cohen
Journal:  Clin Pharmacol Ther       Date:  1992-10       Impact factor: 6.875

2.  Estimating impossible curves using NONMEM.

Authors:  R C Schoemaker; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1996-09       Impact factor: 4.335

3.  A suitable parameterization of the Michaelis-Menten enzyme reaction.

Authors:  D A Ratkowsky
Journal:  Biochem J       Date:  1986-12-01       Impact factor: 3.857

4.  On the identification of Michaelis-Menten elimination parameters from a single dose-response curve.

Authors:  K R Godfrey; W R Fitch
Journal:  J Pharmacokinet Biopharm       Date:  1984-04

Review 5.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

6.  Computational problems of compartment models with Michaelis-Menten-type elimination.

Authors:  C M Metzler; D D Tong
Journal:  J Pharm Sci       Date:  1981-07       Impact factor: 3.534

7.  Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects.

Authors:  J Dingemanse; J M van Gerven; R C Schoemaker; G Roncari; J J Oberyé; M F van Oostenbruggen; J Massarella; P Segala; M Zell; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1997-11       Impact factor: 4.335

8.  Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects.

Authors:  J M van Gerven; G Roncari; R C Schoemaker; J Massarella; P Keesmaat; H Kooyman; P Heizmann; M Zell; A F Cohen; J Dingemanse
Journal:  Br J Clin Pharmacol       Date:  1997-11       Impact factor: 4.335

9.  Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats.

Authors:  O E Della Paschoa; J W Mandema; R A Voskuyl; M Danhof
Journal:  J Pharmacol Exp Ther       Date:  1998-02       Impact factor: 4.030

10.  A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers.

Authors:  A L van Steveninck; H C Schoemaker; M S Pieters; R Kroon; D D Breimer; A F Cohen
Journal:  Clin Pharmacol Ther       Date:  1991-08       Impact factor: 6.875

  10 in total
  17 in total

1.  Drug-drug pharmacodynamic interaction detection by a nonparametric population approach. Influence of design and of interindividual variability.

Authors:  Y Merlé; A Mallet; E Schmautz
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

2.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

3.  Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship.

Authors:  Euitae Kim; Oliver D Howes; Bo-Hyung Kim; Jae Min Jeong; Jae Sung Lee; In-Jin Jang; Sang-Goo Shin; Federico E Turkheimer; Shitij Kapur; Jun Soo Kwon
Journal:  J Cereb Blood Flow Metab       Date:  2011-12-21       Impact factor: 6.200

4.  Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses.

Authors:  Lena E Friberg; Geoffrey K Isbister; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

5.  Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Núria Buil-Bruna; Marion Dehez; Amandine Manon; Thi Xuan Quyen Nguyen; Iñaki F Trocóniz
Journal:  AAPS J       Date:  2016-02-23       Impact factor: 4.009

6.  Predicting the dose of vancomycin in ICU patients receiving different types of RRT therapy: a model-based meta-analytic approach.

Authors:  Guillaume Claisse; Paul J Zufferey; Jane C Trone; Nicolas Maillard; Xavier Delavenne; Silvy Laporte; Edouard Ollier
Journal:  Br J Clin Pharmacol       Date:  2019-04-07       Impact factor: 4.335

7.  Optimised protocol design for the screening of analgesic compounds in neuropathic pain.

Authors:  A Taneja; J Nyberg; M Danhof; O Della Pasqua
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-30       Impact factor: 2.745

8.  Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.

Authors:  Elena Soto; Ron J Keizer; Iñaki F Trocóniz; Alwin D R Huitema; Jos H Beijnen; Jan H M Schellens; Jantien Wanders; Josep María Cendrós; Rosendo Obach; Concepción Peraire; Lena E Friberg; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2010-05-07       Impact factor: 3.850

9.  Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Authors:  Mats O Karlsson; Irja Lutsar; Peter A Milligan
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

10.  Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.

Authors:  Matthew M Riggs; Leo J Seman; Alexander Staab; Thomas R MacGregor; William Gillespie; Marc R Gastonguay; Hans J Woerle; Sreeraj Macha
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.